Physician profile
George M Frank
NPI 1417918061
$8,620.79
in general payments reported to CMS, 2019-2025
44 companies · $930 in 2025
The $930 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $1,471 · 2021: $1,475 · 2022: $878 · 2023: $1,360 · 2024: $1,109 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.88 | 2019-2025 | |
| Pfizer INC. | $960.06 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $823.07 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $774.45 | 2019-2025 | Airsupra, Nexium, Breztri |
| Amgen INC. | $670.92 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $516.99 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $419.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $419.11 | 2020-2025 | Mounjaro, Kisunla, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.61 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $287.18 | 2019-2024 | Dificid, Gardasil 9, Pneumovax 23 |
| Bayer Healthcare Pharmaceuticals INC. | $213.07 | 2021-2025 | |
| Allergan, INC. | $204.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $172.67 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $168.37 | 2020-2024 | Seglentis, Livalo |
| Astellas Pharma US INC | $164.78 | 2019-2025 | Veozah, Myrbetriq |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.